Literature DB >> 15661535

Targeting Ras and Rho GTPases as opportunities for cancer therapeutics.

Katharine Walker1, Michael F Olson.   

Abstract

The Ras and Rho GTPases contribute to the initiation and progression of cancer by subverting the normal regulation of specific intracellular signalling pathways. As a result, Ras and Rho play significant roles in the development of numerous aspects of the malignant phenotype by promoting cell cycle progression, resistance to apoptotic stimuli, neo-vascularisation and tumour cell motility, invasiveness and metastasis. With these GTPases contributing at so many levels, they are appealing targets for the development of cancer chemotherapeutic agents.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15661535     DOI： 10.1016/j.gde.2004.11.001

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN： 0959-437X            Impact factor:   5.578


  42 in total

1.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

2.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

3.  Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

Authors:  Tatiana Y Prudnikova; Sonali J Rawat; Jonathan Chernoff
Journal:  Clin Cancer Res       Date:  2014-10-21       Impact factor: 12.531

4.  The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms.

Authors:  Daniel R Croft; Michael F Olson
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

5.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

6.  Inhibition of Ras-Effector Interaction by Cyclic Peptides.

Authors:  Xianghong Wu; Punit Upadhyaya; Miguel A Villalona-Calero; Roger Briesewitz; Dehua Pei
Journal:  Medchemcomm       Date:  2013-02-01       Impact factor: 3.597

7.  Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis.

Authors:  Adam B Castoreno; Yegor Smurnyy; Angelica D Torres; Martha S Vokes; Thouis R Jones; Anne E Carpenter; Ulrike S Eggert
Journal:  Nat Chem Biol       Date:  2010-05-02       Impact factor: 15.040

8.  A novel statin-mediated "prenylation block-and-release" assay provides insight into the membrane targeting mechanisms of small GTPases.

Authors:  Bassam R Ali; Ian Nouvel; Ka Fai Leung; Alistair N Hume; Miguel C Seabra
Journal:  Biochem Biophys Res Commun       Date:  2010-05-13       Impact factor: 3.575

9.  Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.

Authors:  Junwang Xu; Fraz A Ismat; Tao Wang; Min Min Lu; Nicole Antonucci; Jonathan A Epstein
Journal:  Circ Res       Date:  2009-07-02       Impact factor: 17.367

10.  A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion.

Authors:  S Hooper; C Gaggioli; E Sahai
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.